Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas

This phase 1 study evaluated frontline brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone (BV+CHP; 6 cycles, then up to 10 cycles of brentuximab vedotin monotherapy) in 26 patients with CD30(+) peripheral T-cell lymphoma, including 19 with systemic anaplastic large...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood
Päätekijät: Fanale, Michelle A., Horwitz, Steven M., Forero-Torres, Andres, Bartlett, Nancy L., Advani, Ranjana H., Pro, Barbara, Chen, Robert W., Davies, Andrew, Illidge, Tim, Uttarwar, Mayur, Lee, Shih-Yuan, Ren, Hong, Kennedy, Dana A., Shustov, Andrei R.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2018
Aiheet:
Clinical Trials and Observations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5946765/
https://ncbi.nlm.nih.gov/pubmed/29507077
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-12-821009
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia